127 related articles for article (PubMed ID: 38198953)
1. Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling.
Adchariyasakulchai P; Sakunrangsit N; Chokyakorn S; Suksanong C; Ketchart W
Biomed Pharmacother; 2024 Feb; 171():116142. PubMed ID: 38198953
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
[TBL] [Abstract][Full Text] [Related]
4. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway.
Siatis KE; Giannopoulou E; Manou D; Sarantis P; Karamouzis MV; Raftopoulou S; Fasseas K; Alzahrani FM; Kalofonos HP; Theocharis AD
Am J Physiol Cell Physiol; 2023 Sep; 325(3):C708-C720. PubMed ID: 37575061
[TBL] [Abstract][Full Text] [Related]
5. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
6. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
7. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
8. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.
Rouhrazi H; Turgan N; Oktem G
Biotech Histochem; 2018; 93(2):77-88. PubMed ID: 29300112
[TBL] [Abstract][Full Text] [Related]
11. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE
Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550
[TBL] [Abstract][Full Text] [Related]
14. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
[TBL] [Abstract][Full Text] [Related]
15. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
16. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
17. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
Thrane S; Lykkesfeldt AE; Larsen MS; Sorensen BS; Yde CW
Breast Cancer Res Treat; 2013 May; 139(1):71-80. PubMed ID: 23609470
[TBL] [Abstract][Full Text] [Related]
20. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]